Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.47 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.42 |
| ▸ | LCAT | P04180 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15014494 | 0.84 | HRH3 (0.54) | HRH3CHRM4MALT1PANK3HTR7 | |
| SCHEMBL13622626 | 0.82 | CHRM4 (0.56) | HRH3CHRM4MALT1PANK3HTR7 | |
| SCHEMBL20064100 | 0.81 | HRH3 (0.51) | HRH3CHRM4MALT1PANK3HTR7 | |
| SCHEMBL12384455 | 0.81 | HRH3 (0.51) | HRH3CHRM4MALT1PANK3HTR7 | |
| Hydrochloric Acid SCHEMBL3288531 | 0.80 | HRH3 (0.50) | HRH3CHRM4MALT1PANK3HTR7 | |
| SCHEMBL12424419 | 0.79 | GPR119 (0.55) | CHRM4PANK3DPP4 | |
| SCHEMBL20064451 | 0.79 | PANK3 (0.49) | HRH3MALT1PANK3HTR7USP30 | |
| SCHEMBL17371895 | 0.79 | CNR2 (0.51) | HRH3CHRM4MALT1PANK3HTR7 | |
| SCHEMBL31472951 | 0.79 | CNR2 (0.51) | HRH3CHRM4MALT1PANK3HTR7 | |
| SCHEMBL25818614 | 0.78 | KDM4E (0.58) | HRH3CHRM4MALT1PANK3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | HRH3 83/4885CHRM4 2225/4885MALT1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.